📣 VC round data is live. Check it out!

Pacira BioSciences Valuation Multiples

Discover Pacira BioSciences' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like GNI Group, MeiraGTx, Biotest, Keqian Biology and more.

Pacira BioSciences Overview

About Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.


Founded

2006

HQ

United States

Employees

790

Website

pacira.com

Financials (LTM)

Revenue: $743M
EBITDA: $185M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pacira BioSciences Financials

Pacira BioSciences reported last 12-month revenue of $743M and EBITDA of $185M.

In the same LTM period, Pacira BioSciences generated $593M in gross profit, $185M in EBITDA, and $122M in net income.

Revenue (LTM)


Pacira BioSciences P&L

In the most recent fiscal year, Pacira BioSciences reported revenue of $726M and EBITDA of $186M.

Pacira BioSciences is profitable as of last fiscal year, with gross margin of 79%, EBITDA margin of 26%, and net margin of 17%.

See analyst estimates for Pacira BioSciences
LTMLast FY202320242025202620272028
Revenue$743M$726M$675M$701M$726M
Gross Profit$593M$577M$490M$531M$577M
Gross Margin80%79%73%76%79%
EBITDA$185M$186M$155M$29M$123M
EBITDA Margin25%26%23%4%17%
EBIT Margin15%22%13%13%3%
Net Profit$122M$124M$42M($100M)$7M
Net Margin16%17%6%(14%)1%
Net Debt-$214M---

Financial data powered by Morningstar, Inc.

Pacira BioSciences Stock Performance

Pacira BioSciences has current market cap of $902M, and enterprise value of $1B.

Market Cap Evolution


Pacira BioSciences' stock price is $22.93.

Pacira BioSciences share price decreased by 1.3% in the last 30 days, and by 4.0% in the last year.

Pacira BioSciences has an EPS (earnings per share) of $3.14.

See more trading valuation data for Pacira BioSciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$902M-1.3%-1.3%1.5%-4.0%$3.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pacira BioSciences Valuation Multiples

Pacira BioSciences trades at 1.5x EV/Revenue multiple, and 6.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Pacira BioSciences

EV / Revenue (LTM)


Pacira BioSciences Financial Valuation Multiples

As of June 2, 2026, Pacira BioSciences has market cap of $902M and EV of $1B.

Pacira BioSciences has a P/E ratio of 7.4x.

LTMLast FY202320242025202620272028
EV/Revenue1.5x1.5x1.6x1.6x1.5x
EV/EBITDA6.0x6.0x7.2x38.2x9.1x
EV/EBIT10.0x7.0x12.7x12.4x57.9x
EV/Gross Profit1.9x1.9x2.3x2.1x1.9x
P/E7.4x7.3x21.5x(9.1x)128.3x
EV/FCF7.9x8.1x8.0x6.2x8.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pacira BioSciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pacira BioSciences Margins & Growth Rates

Pacira BioSciences grew revenue by 6% but EBITDA decreased by 1% in the last fiscal year.

In the most recent fiscal year, Pacira BioSciences reported gross margin of 79%, EBITDA margin of 26%, and net margin of 17%.

See estimated margins and future growth rates for Pacira BioSciences

Pacira BioSciences Margins

Last FY202420252026202720282029
Gross Margin79%76%79%79%
EBITDA Margin26%4%17%24%
EBIT Margin22%13%3%6%
Net Margin17%(14%)1%16%
FCF Margin19%26%19%19%

Pacira BioSciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%4%4%6%
Gross Profit Growth5%8%9%5%
EBITDA Growth(1%)(81%)321%50%
EBIT Growth(71%)3%(79%)141%
Net Profit Growth(3%)(337%)(107%)1596%
FCF Growth6%28%(24%)6%

Data powered by FactSet, Inc. and Morningstar, Inc.

Pacira BioSciences Operational KPIs

Pacira BioSciences' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.7M for the same period.

Pacira BioSciences' Rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pacira BioSciences' Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Pacira BioSciences
LTMLast FY202320242025202620272028
Rule of 4032%30%---
Bessemer Rule of X42%38%---
Revenue per Employee-$0.9M---
Opex per Employee-$0.7M---
S&M Expenses to Revenue-31%23%25%31%
G&A Expenses to Revenue-20%17%17%20%
R&D Expenses to Revenue16%16%11%12%16%
Opex to Revenue-77%60%63%77%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pacira BioSciences Competitors

Pacira BioSciences competitors include GNI Group, MeiraGTx, Biotest, Keqian Biology, Annexon, Sana Biotechnology, Supriya Lifescience, Jade Biosciences, Lexicon Pharmaceuticals and SPIMACO - ADDWAEIH.

Most Pacira BioSciences public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
GNI Group4.4x4.3x(70.2x)423.9x
MeiraGTx11.3x13.6x(10.3x)-
Biotest----
Keqian Biology4.5x4.4x7.3x7.7x
Annexon--(3.3x)(3.4x)
Sana Biotechnology--(4.7x)(4.8x)
Supriya Lifescience10.1x9.8x27.4x27.7x
Jade Biosciences--(5.3x)-

This data is available for Pro users. Sign up to see all Pacira BioSciences competitors and their valuation data.

Start Free Trial

Acquisitions by Pacira BioSciences

Pacira BioSciences has acquired 3 companies to date.

Last acquisition by Pacira BioSciences was on February 27th 2025. Pacira BioSciences acquired GQ Bio Therapeutics for $32M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Pacira BioSciences

GQ Bio Therapeutics
Flexion Therapeutics
MyoScience
Description
GQ Bio Therapeutics is a biotechnology company developing gene therapies and pharmaceuticals targeting osteoarthritis. Headquartered in the United States, it advances intra-articular gene delivery systems to regenerate cartilage and reduce inflammation. The firm's pipeline includes adeno-associated virus vectors delivering therapeutic genes to joint tissues. GQ Bio Therapeutics collaborates on preclinical and clinical programs to address unmet needs in degenerative joint diseases.
Flexion Therapeutics is a biopharmaceutical company specializing in therapies for osteoarthritis and other musculoskeletal disorders. Its FDA-approved product Zilretta delivers extended-release triamcinolone acetonide via intra-articular injection for knee pain management lasting up to three months. Headquartered in Burlington, Massachusetts, Flexion partners with pharmaceutical firms to advance drug candidates from clinical proof-of-concept through commercialization while sharing development risks. The company expanded portfolios through collaborations on injectable therapeutics before its acquisition by Pacira BioSciences in 2022.
MyoScience Inc. is a Redwood City, California-headquartered medical device company developing cryotherapy technologies for aesthetic dermatology. Its core product Cryo-T delivers precise sub-zero temperatures via handheld tips to temporarily freeze sensory nerves, reducing wrinkles in areas like the nasolabial folds and crow's feet. Founded in 2005, the company secured FDA clearance for Cryo-T in 2013 before Allergan acquired it in 2017, integrating the technology into broader aesthetic portfolios.
HQ CountryGermanyUnited StatesUnited States
HQ City
Hamburg
Boston, MA
San Francisco, CA
Deal Date27 Feb 202511 Oct 20215 Mar 2019
Valuation$32M$550M$120M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Pacira BioSciences acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Pacira BioSciences

Pacira BioSciences has invested in 7 companies to date.

Latest investment by Pacira BioSciences was on February 8th 2023. Pacira BioSciences invested in Spine BioPharma in their $13M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Pacira BioSciences

Spine BioPharma
CarthroniX
Spine BioPharma
Genascence
Description
Spine BioPharma advances non-surgical therapies for degenerative spine diseases targeting pain reduction, function restoration, and disease progression halt without opioids. The pipeline includes anti-inflammatory injectables and biologics tested in clinical settings to treat millions affected by chronic back conditions globally.
CarthroniX is a San Diego-based biopharmaceutical company advancing small-molecule drugs for osteoarthritis and cartilage repair. Lead candidate CTX-001 preserves joint matrix while reducing inflammation in preclinical rabbit models. CarthroniX targets knee and hip degeneration with oral therapies entering Phase 1 trials in 2023.
Spine BioPharma advances non-surgical therapies for degenerative spine diseases targeting pain reduction, function restoration, and disease progression halt without opioids. The pipeline includes anti-inflammatory injectables and biologics tested in clinical settings to treat millions affected by chronic back conditions globally.
Genascence is a clinical-stage biotechnology company developing gene therapies for musculoskeletal disorders, particularly osteoarthritis. Based in Pittsburgh, Pennsylvania, the firm delivers genetic payloads via adeno-associated viruses to regenerate cartilage and reduce pain. Its lead candidate targets common knee OA, addressing a condition affecting over 30 million Americans as a risk factor for chronic disability.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
New York City, NY
Lancaster, PA
New York City, NY
San Francisco, CA
Deal Date8 Feb 202311 Apr 202223 Mar 20227 Jan 2022
RoundSeries ASeedSeries BSeries A
Raised$13M$2M$13M$11M
InvestorsCercano Management; Pacira BioSciences; Viscogliosi BrothersPacira BioSciencesCercano Management; Pacira BioSciences; Viscogliosi BrothersDeepWork Capital; Pacira BioSciences; Polymerase Capital; University of Florida Research Foundation
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Pacira BioSciences investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pacira BioSciences

When was Pacira BioSciences founded?Pacira BioSciences was founded in 2006.
Where is Pacira BioSciences headquartered?Pacira BioSciences is headquartered in United States.
How many employees does Pacira BioSciences have?As of today, Pacira BioSciences has over 790 employees.
Who is the CEO of Pacira BioSciences?Pacira BioSciences' CEO is Frank D. Lee.
Is Pacira BioSciences publicly listed?Yes, Pacira BioSciences is a public company listed on Nasdaq.
What is the stock symbol of Pacira BioSciences?Pacira BioSciences trades under PCRX ticker.
When did Pacira BioSciences go public?Pacira BioSciences went public in 2011.
Who are competitors of Pacira BioSciences?Pacira BioSciences main competitors include GNI Group, MeiraGTx, Biotest, Keqian Biology, Annexon, Sana Biotechnology, Supriya Lifescience, Jade Biosciences, Lexicon Pharmaceuticals, SPIMACO - ADDWAEIH.
What is the current market cap of Pacira BioSciences?Pacira BioSciences' current market cap is $902M.
What is the current revenue of Pacira BioSciences?Pacira BioSciences' last 12 months revenue is $743M.
What is the current revenue growth of Pacira BioSciences?Pacira BioSciences revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Pacira BioSciences?Current revenue multiple of Pacira BioSciences is 1.5x.
What is the current EBITDA of Pacira BioSciences?Pacira BioSciences' last 12 months EBITDA is $185M.
What is Pacira BioSciences' EBITDA margin?Pacira BioSciences' last 12 months EBITDA margin is 25%.
What is the current EV/EBITDA multiple of Pacira BioSciences?Current EBITDA multiple of Pacira BioSciences is 6.0x.
What is the current FCF of Pacira BioSciences?Pacira BioSciences' last 12 months FCF is $140M.
What is Pacira BioSciences' FCF margin?Pacira BioSciences' last 12 months FCF margin is 19%.
What is the current EV/FCF multiple of Pacira BioSciences?Current FCF multiple of Pacira BioSciences is 7.9x.
How many companies Pacira BioSciences has acquired to date?As of June 2026, Pacira BioSciences has acquired 3 companies.
What was the largest acquisition by Pacira BioSciences?$550M acquisition of Flexion Therapeutics on 11th October 2021 was the largest M&A Pacira BioSciences has done to date.
What companies Pacira BioSciences acquired?Pacira BioSciences acquired Flexion Therapeutics, MyoScience, and GQ Bio Therapeutics.
In how many companies Pacira BioSciences has invested to date?As of June 2026, Pacira BioSciences has invested in 7 companies.
What was the last Pacira BioSciences investment?On 8th February 2023 Pacira BioSciences invested in Spine BioPharma, participating in a $13M Series A round, alongside Cercano Management and Viscogliosi Brothers.
In what companies Pacira BioSciences invested in?Pacira BioSciences invested in CODA Biotherapeutics, TELA Bio, Spine BioPharma, Genascence, GeneQuine Biotherapeutics, CarthroniX, and AVALON.AI.

See public comps similar to Pacira BioSciences

Lists including Pacira BioSciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial